GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theratechnologies Inc (NAS:THTX) » Definitions » LT-Debt-to-Total-Asset

Theratechnologies (Theratechnologies) LT-Debt-to-Total-Asset : 0.64 (As of Feb. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Theratechnologies LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Theratechnologies's long-term debt to total assests ratio for the quarter that ended in Feb. 2024 was 0.64.

Theratechnologies's long-term debt to total assets ratio increased from Feb. 2023 (0.49) to Feb. 2024 (0.64). It may suggest that Theratechnologies is progressively becoming more dependent on debt to grow their business.


Theratechnologies LT-Debt-to-Total-Asset Historical Data

The historical data trend for Theratechnologies's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theratechnologies LT-Debt-to-Total-Asset Chart

Theratechnologies Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 0.55 0.47 0.02 0.66

Theratechnologies Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.57 0.01 0.66 0.64

Theratechnologies LT-Debt-to-Total-Asset Calculation

Theratechnologies's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Nov. 2023 is calculated as

LT Debt to Total Assets (A: Nov. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Nov. 2023 )/Total Assets (A: Nov. 2023 )
=51.261/77.769
=0.66

Theratechnologies's Long-Term Debt to Total Asset Ratio for the quarter that ended in Feb. 2024 is calculated as

LT Debt to Total Assets (Q: Feb. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Feb. 2024 )/Total Assets (Q: Feb. 2024 )
=46.355/72.09
=0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theratechnologies  (NAS:THTX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Theratechnologies LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Theratechnologies's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Theratechnologies (Theratechnologies) Business Description

Traded in Other Exchanges
Address
2015, rue Peel, 11e etage, Montreal, QC, CAN, H3A 1T8
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.